Gilead Sciences, Inc. $GILD Shares Sold by denkapparat Operations GmbH

denkapparat Operations GmbH lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 35.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 6,940 shares of the biopharmaceutical company’s stock after selling 3,802 shares during the quarter. denkapparat Operations GmbH’s holdings in Gilead Sciences were worth $769,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. One Wealth Advisors LLC raised its holdings in Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after acquiring an additional 2,364 shares in the last quarter. Ariel Investments LLC increased its position in shares of Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after purchasing an additional 30,630 shares during the last quarter. Wealth Management Associates Inc. acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $255,000. Sivik Global Healthcare LLC lifted its position in shares of Gilead Sciences by 25.0% during the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Covea Finance lifted its position in shares of Gilead Sciences by 69.5% during the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock worth $5,732,000 after purchasing an additional 21,200 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the completion of the transaction, the insider directly owned 110,193 shares in the company, valued at approximately $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 71,500 shares of company stock valued at $8,336,040. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $122.56 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a fifty day moving average price of $116.79 and a 200 day moving average price of $112.48. The company has a market cap of $152.07 billion, a P/E ratio of 24.41, a PEG ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $133.00 price objective on shares of Gilead Sciences in a report on Friday, October 31st. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. TD Cowen upped their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Finally, BMO Capital Markets boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $128.27.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.